A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new ...

Geoffrey Hinton was awarded a Nobel Prize in physics on Tuesday in recognition of his trailblazing contributions to the field ...

The FDA has granted Fast Track designation to zilganersen for the treatment of Alexander disease, a rare type of leukodystrophy.

Following the conference, the presentations presented at the 29 th Annual Congress of the WMS will be available on the Investors page of PepGen’s website under Scientific Publications.

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Oral presentation: “Oligonucleotide guided RNA editing of SLC10A1 (NTCP) as a therapeutic approach to lower bile acid re-uptake in cholestatic diseases” Following OTS, the slide deck will be available ...

Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

Researchers from Splisense Ltd. and affiliated organizations recently reported preclinical data for SPL-84, an inhaled antisense oligonucleotide drug candidate being developed for the treatment of ...